IdentificationGeneric Name(13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONEDrugBank Accession NumberDB06888BackgroundNot AvailableTypeSmall MoleculeGroupsExperimentalStructure


3DDownload MOLSDF3D-SDFPDBSMILESInChI


 Similar StructuresStructure for (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE (DB06888)× CloseWeightAverage: 403.4338 Monoisotopic: 403.164439563 Chemical FormulaC22H21N5O3SynonymsNot AvailablePharmacologyIndicationNot AvailableReduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.See how  Build, train, & validate predictive machine-learning models with structured datasets.See howContraindications & Blackbox WarningsAvoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Learn more  Avoid life-threatening adverse drug events & improve clinical decision support.Learn morePharmacodynamicsNot AvailableMechanism of actionTargetActionsOrganismUCyclin-dependent kinase 2Not AvailableHumansAbsorptionNot AvailableVolume of distributionNot AvailableProtein bindingNot AvailableMetabolismNot AvailableRoute of eliminationNot AvailableHalf-lifeNot AvailableClearanceNot AvailableAdverse EffectsImprove decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Learn more  Improve decision support & research outcomes with our structured adverse effects data.Learn moreToxicityNot AvailablePathwaysNot AvailablePharmacogenomic Effects/ADRs 


Not AvailableInteractionsDrug Interactions 


This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist. Not AvailableFood InteractionsNot AvailableCategoriesDrug CategoriesNot AvailableChemical TaxonomyProvided by ClassyfireDescriptionThis compound belongs to the class of organic compounds known as quinoxalines. These are compounds containing a quinoxaline moiety, a bicyclic heterocycle made up of a benzene ring fused to a pyrazine ring.KingdomOrganic compoundsSuper ClassOrganoheterocyclic compoundsClassDiazanaphthalenesSub ClassBenzodiazinesDirect ParentQuinoxalinesAlternative ParentsIndazoles / Alkyl aryl ethers / Pyrazolones / Pyrazines / N-alkylpyrrolidines / Benzenoids / Vinylogous amides / Pyrazoles / Heteroaromatic compounds / Trialkylamines / Lactams / Oxacyclic compounds / Azacyclic compounds / Hydrocarbon derivatives / Organic oxides / Organopnictogen compounds


 show 6 moreSubstituentsAlkyl aryl ether / Amine / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzopyrazole / Ether / Heteroaromatic compound / Hydrocarbon derivative / Indazole / Lactam / N-alkylpyrrolidine / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Oxacycle / Pyrazine / Pyrazole / Pyrazolinone / Pyrrolidine / Quinoxaline / Tertiary aliphatic amine / Tertiary amine / Vinylogous amide


 show 18 moreMolecular FrameworkAromatic heteropolycyclic compoundsExternal DescriptorsNot AvailableAffected organismsNot AvailableChemical IdentifiersUNIINot AvailableCAS numberNot AvailableInChI KeyKBLPHMRCKHFBJB-OLZOCXBDSA-NInChIInChI=1S/C22H21N5O3/c1-12-10-13-11-26(12)8-9-27-22(29)15-5-2-4-14(18(15)25-27)19-21(28)23-16-6-3-7-17(30-13)20(16)24-19/h2-7,12-13,25H,8-11H2,1H3,(H,23,28)/t12-,13+/m1/s1IUPAC Name(13R,15S)-13-methyl-16-oxa-8,9,12,22,24-pentaazahexacyclo[15.6.2.1^{6,9}.1^{12,15}.0^{2,7}.0^{21,25}]heptacosa-1(24),2(7),3,5,17,19,21(25)-heptaene-23,27-dioneSMILES[H][C@]12CN(CCN3NC4=C(C=CC=C4C3=O)C3=NC4=C(NC3=O)C=CC=C4O1)[C@]([H])(C)C2ReferencesGeneral ReferencesNot AvailableExternal LinksPubChem Compound16046126PubChem Substance99443359ChemSpider13174538BindingDB50192071ZINCZINC000003820290PDBe Ligand1CDPDB Entries2ds1Clinical TrialsClinical Trials 


PhaseStatusPurposeConditionsCountPharmacoeconomicsManufacturersNot AvailablePackagersNot AvailableDosage FormsNot AvailablePricesNot AvailablePatentsNot AvailablePropertiesStateSolidExperimental PropertiesNot AvailablePredicted PropertiesPropertyValueSourceWater Solubility0.335 mg/mLALOGPSlogP1.86ALOGPSlogP2.14ChemaxonlogS-3.1ALOGPSpKa (Strongest Acidic)8.57ChemaxonpKa (Strongest Basic)7.9ChemaxonPhysiological Charge1ChemaxonHydrogen Acceptor Count6ChemaxonHydrogen Donor Count2ChemaxonPolar Surface Area86.27 Å2ChemaxonRotatable Bond Count0ChemaxonRefractivity116.32 m3·mol-1ChemaxonPolarizability42.01 Å3ChemaxonNumber of Rings6ChemaxonBioavailability1ChemaxonRule of FiveYesChemaxonGhose FilterYesChemaxonVeber's RuleNoChemaxonMDDR-like RuleNoChemaxonPredicted ADMET FeaturesPropertyValueProbabilityHuman Intestinal Absorption+1.0Blood Brain Barrier+0.7265Caco-2 permeable-0.6081P-glycoprotein substrateSubstrate0.8071P-glycoprotein inhibitor INon-inhibitor0.5129P-glycoprotein inhibitor IINon-inhibitor0.9302Renal organic cation transporterNon-inhibitor0.6758CYP450 2C9 substrateNon-substrate0.8791CYP450 2D6 substrateNon-substrate0.6851CYP450 3A4 substrateSubstrate0.6624CYP450 1A2 substrateNon-inhibitor0.8396CYP450 2C9 inhibitorNon-inhibitor0.8381CYP450 2D6 inhibitorNon-inhibitor0.7095CYP450 2C19 inhibitorNon-inhibitor0.6885CYP450 3A4 inhibitorNon-inhibitor0.9182CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7216Ames testAMES toxic0.5277CarcinogenicityNon-carcinogens0.7898BiodegradationNot ready biodegradable1.0Rat acute toxicity2.6409 LD50, mol/kg Not applicablehERG inhibition (predictor I)Weak inhibitor0.7555hERG inhibition (predictor II)Non-inhibitor0.6733  ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397) SpectraMass Spec (NIST)Not AvailableSpectraSpectrumSpectrum TypeSplash KeyPredicted GC-MS Spectrum - GC-MSPredicted GC-MSNot AvailablePredicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot AvailablePredicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot AvailableTargetsBuild, predict & validate machine-learning modelsUse our structured and evidence-based datasets to unlock newinsights and accelerate drug research.Learn more  Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.Learn moreBinding Properties×PropertyMeasurementpHTemperature (°C)ReferencesIC 50 (nM)3.4N/AN/AA30693


 Details


 Binding Properties1. Cyclin-dependent kinase 2KindProteinOrganismHumansPharmacological actionUnknownGeneral FunctionMetal ion bindingSpecific FunctionSerine/threonine-protein kinase involved in the control of the cell cycle; essential for meiosis, but dispensable for mitosis. Phosphorylates CTNNB1, USP37, p53/TP53, NPM1, CDK7, RB1, BRCA2, MYC, N...Gene NameCDK2Uniprot IDP24941Uniprot NameCyclin-dependent kinase 2Molecular Weight33929.215 DaReferencesBerman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article] ×Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice. Learn more   Drug created at September 15, 2010 21:17 / Updated at June 12, 2020 16:52 